Eli Lilly Acquires Near-Insolvent Cell Therapy Startup Kelonia for $3.2B, Raising Questions on Biotech Valuation

Eli Lilly is set to acquire Kelonia Therapeutics for $3.2 billion, acquiring a company that came within days of insolvency on three separate occasions and operated on a shoestring budget of $60 million over five years. The acquisition, announced this week, represents a striking reversal of fortune for the privately held startup developing cell therapies for cancer and autoimmune diseases. The deal also includes potential milestone payments that could push the total payout to over $6 billion.

The transaction highlights the intense competition among major pharmaceutical companies to secure position in the cell therapy space, a field that has shown remarkable clinical promise but often struggles with financial sustainability. Kelonia was incubated by venture capital firm Venrock, which provided critical support during periods when the company's cash position became critical. According to commentary from Venrock partner Bryan Roberts on STAT's biotech podcast, the company's survival through multiple near-death experiences reflects both the volatility and potential upside inherent in early-stage biotech investment.

The acquisition raises questions about valuation metrics in the current biotech M&A landscape. Kelonia's modest funding history contrasts sharply with the acquisition price, suggesting Eli Lilly may be paying a premium for platform technology or pipeline assets rather than proven revenue. For the broader sector, the deal signals continued large-pharma appetite for oncology and autoimmune assets, even as smaller developers remain financially vulnerable. Analysts will watch whether milestone conditions are met, which would validate the higher end of the valuation range and potentially influence future deal structures in the cell therapy space.